

# Pierfrancesco Tassone

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6366730/pierfrancesco-tassone-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

281  
papers

12,625  
citations

63  
h-index

99  
g-index

289  
ext. papers

14,182  
ext. citations

5.7  
avg, IF

5.85  
L-index

#	Paper	IF	Citations
281	Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report.. <i>Therapeutic Advances in Chronic Disease</i> , <b>2022</b> , 13, 20406223211063024	4.9	1
280	Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes.. <i>Cells</i> , <b>2022</b> , 11,	7.9	2
279	miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.. <i>Molecular Therapy - Nucleic Acids</i> , <b>2022</b> , 27, 1191-1224	10.7	1
278	Integration of DNA Microarray with Clinical and Genomic Data.. <i>Methods in Molecular Biology</i> , <b>2022</b> , 2401, 239-248	1.4	
277	Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 548	5.2	0
276	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , <b>2022</b> , 7, 100459	6.5	1
275	A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics. <i>Biomedicines</i> , <b>2022</b> , 10, 1210	4.8	
274	Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. <i>Haematologica</i> , <b>2021</b> , 106, 185-195	6.6	19
273	Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. <i>Life</i> , <b>2021</b> , 11,	3	3
272	Personalized Medicine. <i>UNIPA Springer Series</i> , <b>2021</b> , 391-399	0.1	
271	miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	21
270	Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' Heel. <i>Cancers</i> , <b>2021</b> , 13,	6.6	7
269	Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data. <i>Journal of Computational Science</i> , <b>2021</b> , 51, 101346	3.4	3
268	miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. <i>Leukemia</i> , <b>2021</b> , 35, 823-834	10.7	14
267	Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 113-119	4.9	16
266	In Vitro Silencing of lncRNAs Using LNA GapmeRs. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2348, 157-166	1.4	0
265	Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia <b>2021</b> , 9,		4

264	miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
263	FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , <b>2021</b> ,	7.8	2
262	Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 2658-2668	7.5	5
261	Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 1132-1143	35.1	66
260	Non-coding RNAs in cancer: platforms and strategies for investigating the genomic "dark matter". <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 117	12.8	56
259	Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosity predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade <b>2020</b> , 8,		16
258	Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats. <i>Molecular Therapy - Nucleic Acids</i> , <b>2020</b> , 20, 73-85	10.7	5
257	Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2020</b> , 188, 113451	3.5	1
256	LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?. <i>Non-coding RNA</i> , <b>2020</b> , 6,	7.1	10
255	Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. <i>Scientific Reports</i> , <b>2020</b> , 10, 2565	4.9	35
254	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. <i>Cancers</i> , <b>2020</b> , 12,	6.6	14
253	Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
252	DMET Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine. <i>High-Throughput</i> , <b>2020</b> , 9,	4.3	6
251	On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1712-1719	4.4	
250	Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation. <i>Current Medicinal Chemistry</i> , <b>2020</b> , 27, 187-215	4.3	10
249	Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths. <i>Frontiers in Bioengineering and Biotechnology</i> , <b>2020</b> , 8, 84	5.8	3
248	Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. <i>Oncology Letters</i> , <b>2020</b> , 19, 1559-1566	2.6	26
247	MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers. <i>Lecture Notes in Computer Science</i> , <b>2020</b> , 564-571	0.9	3

246	Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 579445	5.3	6
245	HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. <i>Cells</i> , <b>2020</b> , 9,	7.9	17
244	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. <i>Leukemia</i> , <b>2020</b> , 34, 234-244	10.7	46
243	A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. <i>European Journal of Medicinal Chemistry</i> , <b>2019</b> , 183, 111715	6.8	17
242	Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. <i>MedChemComm</i> , <b>2019</b> , 10, 116-119	5	8
241	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 140, 67-72	7	40
240	Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. <i>Molecular and Clinical Oncology</i> , <b>2019</b> , 11, 81-90	1.6	17
239	miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. <i>Molecular Therapy - Nucleic Acids</i> , <b>2019</b> , 16, 391-406	10.7	21
238	Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 32	22.4	16
237	Alternative non-homologous end joining repair: a master regulator of genomic instability in cancer. <i>Precision Cancer Medicine</i> , <b>2019</b> , 2, 8-8	1	4
236	Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 422-431	6.1	19
235	miR-22 suppresses DNA ligase III addiction in multiple myeloma. <i>Leukemia</i> , <b>2019</b> , 33, 487-498	10.7	29
234	Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	25
233	Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , <b>2019</b> , 9,	3.8	3
232	Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221. <i>Cancers</i> , <b>2019</b> , 12,	6.6	8
231	Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	22
230	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1102	5.3	11
229	An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery. <i>Molecular Therapy - Nucleic Acids</i> , <b>2019</b> , 18, 981-990	10.7	13

228	Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. <i>Haematologica</i> , <b>2019</b> , 104, e72-e76	6.6	20
227	Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. <i>Leukemia</i> , <b>2018</b> , 32, 1948-1957	10.7	129
226	Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). <i>Haematologica</i> , <b>2018</b> , 103, e473-e479	6.6	11
225	The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 125, 69-77	7	7
224	Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 150, 300-307	3.5	15
223	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. <i>Blood</i> , <b>2018</b> , 132, 1050-1063	2.2	40
222	miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2018</b> , 37, 94	12.8	33
221	MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 63	22.4	160
220	The potential role of miRNAs in multiple myeloma therapy. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 793-803	8.03	20
219	MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. <i>Leukemia</i> , <b>2018</b> , 32, 1003-1015	10.7	36
218	Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. <i>Leukemia</i> , <b>2018</b> , 32, 996-1002	10.7	45
217	Mouse models of multiple myeloma: technologic platforms and perspectives. <i>Oncotarget</i> , <b>2018</b> , 9, 20119-20133	3.34	34
216	The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 131, 83-89	7	29
215	Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. <i>Oncotarget</i> , <b>2018</b> , 9, 20539-20554	3.3	11
214	Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. <i>Leukemia</i> , <b>2017</b> , 31, 1894-1904	10.7	23
213	Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. <i>Expert Opinion on Therapeutic Targets</i> , <b>2017</b> , 21, 91-101	6.4	47
212	Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment. <i>Current Cancer Drug Targets</i> , <b>2017</b> , 17, 819-838	2.8	11
211	Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSCLC patients. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, 3123-3131	3.6	15

210	Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. <i>Blood Advances</i> , <b>2017</b> , 1, 455-466	7.8	43
209	Precision Oncology: Present Status and Perspectives. <i>Current Clinical Pathology</i> , <b>2017</b> , 7-26	0.1	
208	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1688-1700	21.7	328
207	The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. <i>Leukemia</i> , <b>2017</b> , 31, 1570-1581	10.7	38
206	Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. <i>Scientific Reports</i> , <b>2017</b> , 7, 17949	4.9	33
205	Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. <i>Oncotarget</i> , <b>2017</b> , 8, 100831-100851	3.3	28
204	Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractionated cisplatin and metronomic etoposide and bevacizumab (mPEBev). <i>Oncotarget</i> , <b>2017</b> , 8, 75904-75913	3.3	18
203	Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. <i>Oncotarget</i> , <b>2017</b> , 8, 106527-106537	3.3	46
202	Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment. <i>Current Drug Targets</i> , <b>2017</b> , 18, 35-55	3	14
201	Functional Analysis of microRNA in Multiple Myeloma. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1375, 181-94	1.4	15
200	Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. <i>Leukemia</i> , <b>2016</b> , 30, 2419-2422	10.7	22
199	The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. <i>Cell Death and Disease</i> , <b>2016</b> , 7, e2299	9.8	15
198	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 1213-1220	4.6	38
197	Challenges in Multiple Myeloma Chemoprevention: Potential Role of Natural, Synthetic and Endogenous Molecules <b>2016</b> , 37-60		1
196	Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates. <i>Molecular Therapy - Nucleic Acids</i> , <b>2016</b> , 5,	10.7	35
195	Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. <i>Pancreatology</i> , <b>2016</b> , 16, 249-58	3.8	12
194	miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e380	7	44
193	Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 77, 205-9	3.5	33

192	Experimental treatment of multiple myeloma in the era of precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2016</b> , 1, 37-51	1.6	3
191	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 367-377	21.7	339
190	Mir-221/222 are promising targets for innovative anticancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , <b>2016</b> , 20, 1099-108	6.4	36
189	Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. <i>Oncolimmunology</i> , <b>2016</b> , 5, e1101205	7.2	21
188	Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. <i>Oncotarget</i> , <b>2016</b> , 7, 82741-82756	3.3	10
187	mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials. <i>Oncotarget</i> , <b>2016</b> , 7, 27055-66	3.3	12
186	Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. <i>Oncotarget</i> , <b>2016</b> , 7, 2367-78	3.3	35
185	DMET (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine. <i>Oncotarget</i> , <b>2016</b> , 7, 54028-54050	3.3	47
184	MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. <i>BioMed Research International</i> , <b>2016</b> , 2016, 6504593	3	42
183	OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes. <i>Microarrays (Basel, Switzerland)</i> , <b>2016</b> , 5,		12
182	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. <i>Future Oncology</i> , <b>2016</b> , 12, 2071-5	3.6	18
181	Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. <i>Journal of Ovarian Research</i> , <b>2016</b> , 9, 31	5.5	29
180	A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e511	7	30
179	Immunotherapy of colorectal cancer: new perspectives after a long path. <i>Immunotherapy</i> , <b>2016</b> , 8, 1281-1292	3.2	17
178	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1364-75	6.1	75
177	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1364-1375	6.1	60
176	A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1222-33	12.9	79
175	lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e468	7	33

174	A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 1148-59	4.6	25
173	Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. <i>Leukemia</i> , <b>2015</b> , 29, 2173-83	10.7	86
172	Multiple myeloma-related bone disease: state-of-art and next future treatments. <i>International Journal of Hematologic Oncology</i> , <b>2015</b> , 4, 33-47	1	
171	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 3150-8	1.9	17
170	Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 1159-73	7.4	19
169	Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. <i>Scientific Reports</i> , <b>2015</b> , 5, 17579	4.9	90
168	Analysis of miRNA, mRNA, and TF interactions through network-based methods. <i>Eurasip Journal on Bioinformatics and Systems Biology</i> , <b>2015</b> , 2015, 4		15
167	Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts. <i>Oncotarget</i> , <b>2015</b> , 6, 27343-58	3.3	78
166	Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. <i>Oncotarget</i> , <b>2015</b> , 6, 13772-89	3.3	124
165	The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. <i>Nature Medicine</i> , <b>2015</b> , 21, 572-80	50.5	60
164	miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. <i>Oncotarget</i> , <b>2015</b> , 6, 12837-61	3.3	95
163	Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. <i>Oncotarget</i> , <b>2015</b> , 6, 19132-47	3.3	37
162	A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. <i>Oncotarget</i> , <b>2015</b> , 6, 26129-41	3.3	30
161	MicroRNAs in multiple myeloma and related bone disease. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 3343,2		15
160	MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2014</b> , 123, 2673-81	2.2	15
159	Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 1394-6	1.9	5
158	Mir-34: a new weapon against cancer?. <i>Molecular Therapy - Nucleic Acids</i> , <b>2014</b> , 3, e194	10.7	358
157	microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4141-53	12.9	41



156	Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes. <i>International Journal of Nanomedicine</i> , <b>2014</b> , 9, 2359-72	7.3	34
155	Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 797-805	4.6	34
154	A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 660-6	8.7	68
153	Aberrant glycosylation as biomarker for cancer: focus on CD43. <i>BioMed Research International</i> , <b>2014</b> , 2014, 742831	3	72
152	Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 348	5.3	48
151	Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. <i>BioMed Research International</i> , <b>2014</b> , 2014, 217365	3	38
150	A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. <i>Journal of Cellular Physiology</i> , <b>2014</b> , 229, 2106-16	7	76
149	Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial. <i>Journal of Immunotherapy</i> , <b>2014</b> , 37, 26-35	5	34
148	Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 707-20	4.6	41
147	In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e89659	3.7	72
146	In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. <i>PLoS ONE</i> , <b>2014</b> , 9, e90005	3.7	90
145	Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. <i>Oncotarget</i> , <b>2014</b> , 5, 3039-54	3.3	80
144	MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. <i>Current Pharmaceutical Biotechnology</i> , <b>2014</b> , 15, 459-67	2.6	40
143	MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 2060-2060	2.2	
142	A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?. <i>Journal of Ovarian Research</i> , <b>2013</b> , 6, 10	5.5	6
141	miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. <i>Journal of Cellular Physiology</i> , <b>2013</b> , 228, 1506-15	7.15	138
140	Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13 Suppl 1, S55-68	5.4	18
139	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. <i>BMC Medical Genomics</i> , <b>2013</b> , 6, 27	3.7	54

138	Immunologic microenvironment and personalized treatment in multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13 Suppl 1, S83-93	5.4	35
137	Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 593-603	7.5	89
136	Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13 Suppl 1, S125-37	5.4	65
135	Emerging pathways as individualized therapeutic target of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13 Suppl 1, S95-109	5.4	34
134	Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5890-900	12.9	50
133	Ink spot lentigo: singular clinical features in a case series of patients. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2013</b> , 26, 953-5	3	5
132	miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. <i>Cell Cycle</i> , <b>2013</b> , 12, 3650-62	4.7	86
131	Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2096-106	12.9	165
130	Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3247-58	12.9	40
129	Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?. <i>Journal of Drug Delivery</i> , <b>2013</b> , 2013, 905091	2.3	47
128	Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3130-42	12.9	76
127	Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 469-75	4.6	75
126	In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. <i>Oncotarget</i> , <b>2013</b> , 4, 242-55	3.3	109
125	From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. <i>Current Drug Targets</i> , <b>2013</b> , 14, 1144-9	3	39
124	DMET-analyzer: automatic analysis of Affymetrix DMET data. <i>BMC Bioinformatics</i> , <b>2012</b> , 13, 258	3.6	52
123	The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. <i>Blood Cancer Journal</i> , <b>2012</b> , 2, e96	7	55
122	Molecular targets for the treatment of multiple myeloma. <i>Current Cancer Drug Targets</i> , <b>2012</b> , 12, 757-672.8		56
121	Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. <i>Blood</i> , <b>2012</b> , 120, 5002-13	2.2	94

120	Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6260-70	12.9	185
119	Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 850-7	12.9	58
118	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. <i>Cell Death and Disease</i> , <b>2012</b> , 3, e436	9.8	122
117	Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1888-900	12.9	61
116	Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. <i>Oncology Reports</i> , <b>2012</b> , 27, 1849-56	3.5	40
115	Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. <i>Onc Immunology</i> , <b>2012</b> , 1, 531-532	7.2	26
114	MicroRNAs in the pathobiology of multiple myeloma. <i>Current Cancer Drug Targets</i> , <b>2012</b> , 12, 823-37	2.8	40
113	Promises and challenges of MicroRNA-based treatment of multiple myeloma. <i>Current Cancer Drug Targets</i> , <b>2012</b> , 12, 838-46	2.8	80
112	Pharmacological Approaches for BRCA1/2 Related Breast and Ovarian Cancer: Preclinical Studies and Early Clinical Trials. <i>Current Womens Health Reviews</i> , <b>2012</b> , 8, 104-110	0.2	
111	Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. <i>Current Cancer Drug Targets</i> , <b>2012</b> , 12, 814-22	2.8	41
110	Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. <i>Journal of Immunotherapy</i> , <b>2012</b> , 35, 440-7	5	30
109	Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.. <i>Blood</i> , <b>2012</b> , 120, 2932-2932	2.2	3
108	Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. <i>Cancer Genomics and Proteomics</i> , <b>2012</b> , 9, 55-66	3.3	8
107	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. <i>Oncotarget</i> , <b>2012</b> , 3, 1246-58	3.3	127
106	The Expression Pattern of Small Nucleolar and Small Cajal Body-Specific RNAs Characterizes Distinct Molecular Subtypes of Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 3955-3955	2.2	
105	Integrin $\beta$ -mediated regulation of multiple myeloma cell adhesion, migration, and invasion. <i>Blood</i> , <b>2011</b> , 117, 6202-13	2.2	104
104	Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. <i>Blood</i> , <b>2011</b> , 118, 6368-79	2.2	95
103	A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling. <i>British Journal of Haematology</i> , <b>2011</b> , 154, 529-33	4.5	58

102	A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. <i>Leukemia</i> , <b>2011</b> , 25, 707-11	10.7	91
101	Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2011</b> , 7, 955-64 <sup>6</sup>		88
100	Automatic summarisation and annotation of microarray data. <i>Soft Computing</i> , <b>2011</b> , 15, 1505-1512	3.5	13
99	Significant biological role of sp1 transactivation in multiple myeloma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6500-9	12.9	44
98	Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein. <i>Molecular and Cellular Proteomics</i> , <b>2011</b> , 10, M111.007898	7.6	19
97	Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. <i>Cancer Biology and Therapy</i> , <b>2011</b> , 12, 780-7	4.6	67
96	Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 9, 685-93	4.6	27
95	Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). <i>European Journal of Cancer</i> , <b>2010</b> , 46, 1703-11	7.5	55
94	Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. <i>Journal of Immunotherapy</i> , <b>2010</b> , 33, 435-45		173
93	SCID-Synth-Hu: a Novel Multiple Myeloma Model for In Vivo Expansion of Primary Cells. <i>Blood</i> , <b>2010</b> , 116, 452-452	2.2	
92	Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 648-53	4.6	78
91	A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7144-52	12.9	98
90	Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 26-35	6.1	46
89	Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. <i>Current Cancer Drug Targets</i> , <b>2009</b> , 9, 854-70	2.8	19
88	Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 497-502	4.6	18
87	Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. <i>Current Cancer Drug Targets</i> , <b>2009</b> , 9, 791-800	2.8	32
86	In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 1009-20	3.5	58
85	BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?. <i>Journal of Ovarian Research</i> , <b>2009</b> , 2, 14	5.5	19

84	Monoclonal Antibody-Based Therapies in Human Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9, S22-S23		
83	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. <i>Blood</i> , <b>2009</b> , 114, 371-2	2.2	31
82	Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. <i>Blood</i> , <b>2009</b> , 114, 3276-84	2.2	31
81	An Extension of the TIGR M4 Suite to Preprocess and Visualize Affymetrix Binary Files. <i>Lecture Notes in Computer Science</i> , <b>2009</b> , 265-274	0.9	1
80	Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. <i>Leukemia</i> , <b>2008</b> , 22, 1410-8	10.7	80
79	p38 mitogen-activated protein kinase inhibitor LY222820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 598-606	4.5	46
78	In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. <i>British Journal of Haematology</i> , <b>2008</b> , 143, 520-31	4.5	53
77	Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1123-32	12.9	63
76	The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 1374-83	1.9	33
75	The IASLC Lung Cancer Staging Project: revision proposal of pleural effusion and controlateral nodule staging. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 317; author reply 317-8	8.9	2
74	Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. <i>Blood</i> , <b>2008</b> , 112, 1346-56	2.2	86
73	The Farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways. <i>International Journal of Cancer</i> , <b>2007</b> , 121, 2317-30	7.5	18
72	Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. <i>Leukemia</i> , <b>2007</b> , 21, 2519-26	10.7	22
71	Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. <i>Experimental Hematology</i> , <b>2007</b> , 35, 1038-46	3.1	16
70	Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. <i>Experimental Hematology</i> , <b>2007</b> , 35, 1366-75	3.1	53
69	Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues. <i>Current Pharmaceutical Design</i> , <b>2007</b> , 13, 487-96	3.3	17
68	Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5903-9	12.9	116
67	Pegylated liposomal doxorubicin is active in Stewart-Treves syndrome. <i>Annals of Oncology</i> , <b>2007</b> , 18, 959-60	10.3	4

66	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. <i>Blood</i> , <b>2007</b> , 110, 1656-63	103
65	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). <i>Blood</i> , <b>2007</b> , 109, 1220-7	2.2 140
64	Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours. <i>Current Signal Transduction Therapy</i> , <b>2007</b> , 2, 165-173	0.8
63	Modulation of Gene Expression Profile and In Vivo Anti-Myeloma Activity Induced by Valproic Acid, a Histone Deacetylase Inhibitor.. <i>Blood</i> , <b>2007</b> , 110, 4790-4790	2.2
62	MLN120B, a novel I $\kappa$ B kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5887-94	12.9 118
61	Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 1640-52	7.5 20
60	Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 1530-8	7.5 25
59	Partial purification and MALDI-TOF MS analysis of UN1, a tumor antigen membrane glycoprotein. <i>International Journal of Biological Macromolecules</i> , <b>2006</b> , 39, 122-6	7.9 6
58	Dysfunctional T regulatory cells in multiple myeloma. <i>Blood</i> , <b>2006</b> , 107, 301-4	2.2 188
57	Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. <i>Blood</i> , <b>2006</b> , 108, 3441-9	2.2 300
56	In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. <i>British Journal of Haematology</i> , <b>2006</b> , 134, 37-44	4.5 16
55	Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. <i>British Journal of Haematology</i> , <b>2006</b> , 134, 145-56	4.5 90
54	Elevated Apurinic/Apyrimidinic Endonuclease Activity Significantly Contributes to DNA Instability in Multiple Myeloma.. <i>Blood</i> , <b>2006</b> , 108, 2077-2077	2.2
53	Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents <b>2005</b> , 26, 1257	4
52	HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. <i>Blood</i> , <b>2005</b> , 105, 251-8	2.2 253
51	A SCID-hu in vivo model of human Waldenström macroglobulinemia. <i>Blood</i> , <b>2005</b> , 106, 1341-5	2.2 35
50	A clinically relevant SCID-hu in vivo model of human multiple myeloma. <i>Blood</i> , <b>2005</b> , 106, 713-6	2.2 109
49	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. <i>Blood</i> , <b>2005</b> , 106, 706-12	2.2 52

48	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. <i>Blood</i> , <b>2005</b> , 105, 4470-6	2.2	54
47	New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2005</b> , 54, 1-10	7.4	74
46	Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4251-8	12.9	88
45	A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma (MM).. <i>Blood</i> , <b>2005</b> , 106, 111-111	2.2	7
44	Establishment of a Waldenstrom's Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. <i>Blood</i> , <b>2005</b> , 106, 979-979	2.2	3
43	Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways. <i>Current Drug Targets</i> , <b>2005</b> , 6, 289-300	3	15
42	Novel Hydroxamic Acid-Derived HDAC Inhibitor LBH589 Potently Activates Intrinsic and Extrinsic Apoptotic Pathways, and Induces Tubulin Hyperacetylation in Multiple Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 1578-1578 <sup>1</sup>	2.2	1
41	Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents. <i>International Journal of Oncology</i> , <b>2005</b> , 26, 1257-63	1	17
40	In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. <i>Cancer Research</i> , <b>2004</b> , 64, 4629-36	10.1	139
39	Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. <i>Cancer Research</i> , <b>2004</b> , 64, 8746-53	10.1	28
38	NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. <i>Leukemia</i> , <b>2004</b> , 18, 11-7	10.7	76
37	The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. <i>Oncogene</i> , <b>2004</b> , 23, 6900-13	9.2	69
36	Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. <i>International Journal of Cancer</i> , <b>2004</b> , 112, 754-9	7.5	89
35	Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. <i>Blood</i> , <b>2004</b> , 104, 3688-96	2.2	111
34	A Clinically Relevant SCID-hu In Vivo Model of Human Multiple Myeloma.. <i>Blood</i> , <b>2004</b> , 104, 2455-2455	2.2	
33	Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. <i>Blood</i> , <b>2004</b> , 104, 2401-2401	2.2	
32	Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.. <i>Blood</i> , <b>2004</b> , 104, 644-644		
31	Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. <i>Blood</i> , <b>2004</b> , 104, 764-764	2.2	

30	Human mismatch-repair protein MutL homologue 1 (MLH1) interacts with Escherichia coli MutL and MutS in vivo and in vitro: a simple genetic system to assay MLH1 function. <i>Biochemical Journal</i> , <b>2003</b> , 371, 183-9	3.8	11
29	BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 1285-91	8.7	298
28	Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 1971-8	8.7	127
27	EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. <i>Cell Death and Differentiation</i> , <b>2003</b> , 10, 218-29	12.7	61
26	The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. <i>Journal of Biochemistry</i> , <b>2003</b> , 133, 757-65	3.1	57
25	The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells <b>2002</b> , 21, 867		3
24	Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. <i>European Journal of Cancer</i> , <b>2002</b> , 38, 1141-7	7.5	10
23	Fetal ontogeny and tumor expression of the early thymic antigen UN1. <i>International Journal of Oncology</i> , <b>2002</b> , 20, 707-11	1	4
22	Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas. <i>Anticancer Research</i> , <b>2002</b> , 22, 2333-40	2.3	6
21	The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. <i>International Journal of Oncology</i> , <b>2002</b> , 21, 867-73	1	19
20	Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. <i>Human Mutation</i> , <b>2001</b> , 18, 163-4	4.7	206
19	Transcriptional regulation of the mismatch repair gene hMLH1. <i>Gene</i> , <b>2001</b> , 275, 261-5	3.8	20
18	Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. <i>Cell Death and Differentiation</i> , <b>2000</b> , 7, 327-8	12.7	29
17	Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides. <i>Gene Therapy</i> , <b>2000</b> , 7, 1234-7	4	39
16	Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. <i>Leukemia</i> , <b>2000</b> , 14, 841-4	10.7	128
15	Detection of microsatellite instability and loss of heterozygosity in serum DNA of small and non-small cell lung cancer patients: a tool for early diagnosis?. <i>Lung Cancer</i> , <b>2000</b> , 30, 211-4	5.9	20
14	Amifostine Inhibits Hematopoietic Progenitor Cell Apoptosis by Activating NF-B/Rel Transcription Factors. <i>Blood</i> , <b>1999</b> , 94, 4060-4066	2.2	2
13	Purification and characterization of a human sialoglycoprotein antigen expressed in immature thymocytes and fetal tissues. <i>Tissue Antigens</i> , <b>1998</b> , 51, 528-35		8



12	CD36 is rapidly and transiently upregulated on phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes. Analysis by a new monoclonal antibody (UN7). <i>Tissue Antigens</i> , <b>1998</b> , 51, 671-5		4
11	Hereditary nonpolyposis colorectal cancer: identification of novel germline mutations in two kindreds not fulfilling the Amsterdam criteria. Mutations in brief no. 203. Online. <i>Human Mutation</i> , <b>1998</b> , 12, 433	4.7	9
10	Identification by differential display of transcripts regulated during hematopoietic differentiation. <i>Stem Cells</i> , <b>1998</b> , 16, 136-43	5.8	10
9	Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , <b>1998</b> , 92, 990-995	2.2	7
8	CD69 expression on primitive progenitor cells and hematopoietic malignancies. <i>Tissue Antigens</i> , <b>1996</b> , 48, 65-8		5
7	Detection of an antigenic marker expressed by peripheral blood monocytes and platelets by a new monoclonal antibody, UN8. <i>Tissue Antigens</i> , <b>1995</b> , 45, 288-91		
6	Analysis of peripheral blood normal and malignant cells with the novel murine monoclonal antibody UN2. <i>Immunology Letters</i> , <b>1994</b> , 42, 55-62	4.1	1
5	A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells. <i>Immunology Letters</i> , <b>1994</b> , 39, 137-46	4.1	1
4	Regulation of NF-kappa B nuclear activity in peripheral blood mononuclear cells: role of CD28 antigen. <i>Cellular Immunology</i> , <b>1994</b> , 156, 371-7	4.4	7
3	UN1, a murine monoclonal antibody recognizing a novel human thymic antigen. <i>Tissue Antigens</i> , <b>1994</b> , 44, 73-82		11
2	Defect of interleukin-2 production and T cell proliferation in atopic patients: restoring ability of the CD28-mediated activation pathway. <i>Cellular Immunology</i> , <b>1993</b> , 148, 455-63	4.4	4
1	Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1. <i>Journal of Virology</i> , <b>1993</b> , 67, 2853-61	6.6	52